Works matching IS 17762596 AND DT 2022 AND VI 17 AND IP 3

Results: 15

Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 343, doi. 10.1007/s11523-022-00880-3

By:

Mizukami, Takuro;
Takahashi, Masaki;
Sunakawa, Yu;
Yuki, Satoshi;
Kagawa, Yoshinori;
Takashima, Atsuo;
Kato, Kyoko;
Hara, Hiroki;
Denda, Tadamichi;
Yamamoto, Yoshiyuki;
Shiozawa, Manabu;
Oki, Eiji;
Okamoto, Wataru;
Yoshino, Takayuki;
Eguchi Nakajima, Takako

Publication type:

Article

Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 355, doi. 10.1007/s11523-022-00886-x

By:

Choo, Joan R. E.;
Jan, Yi-Hua;
Ow, Samuel G. W.;
Wong, Andrea;
Lee, Matilda Xinwei;
Ngoi, Natalie;
Yadav, Kritika;
Lim, Joline S. J.;
Lim, Siew Eng;
Chan, Ching Wan;
Hartman, Mikael;
Tang, Siau Wei;
Goh, Boon Cher;
Tan, Hon Lyn;
Chong, Wan Qin;
Yvonne, Ang Li En;
Chan, Gloria H. J.;
Chen, Shu-Jen;
Tan, Kien Thiam;
Lee, Soo Chin

Publication type:

Article

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Published in:

2022

By:

Scott, Lesley J.

Publication type:

Correction Notice

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 369, doi. 10.1007/s11523-022-00883-0

By:

Frampton, James E.

Publication type:

Article

Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 329, doi. 10.1007/s11523-022-00891-0

By:

Kennedy, Laura C.;
Lu, Jun;
Kuehn, Sydney;
Ramirez, Arturo B.;
Lo, Edward;
Sun, Yao;
U'Ren, Lance;
Chow, Laura Q. M.;
Chen, Zhengjia;
Grivas, Petros;
Kaldjian, Eric P.;
Gadi, Vijayakrishna K.

Publication type:

Article

When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 253, doi. 10.1007/s11523-022-00890-1

By:

Araujo, Daniel V.;
Uchoa, Bruno;
Soto-Castillo, Juan José;
Furlan, Larissa L.;
Oliva, Marc

Publication type:

Article

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 283, doi. 10.1007/s11523-022-00888-9

By:

Trippett, Tanya;
Toledano, Helen;
Campbell Hewson, Quentin;
Verschuur, Arnauld;
Langevin, Anne-Marie;
Aerts, Isabelle;
Howell, Lisa;
Gallego, Soledad;
Rossig, Claudia;
Smith, Amy;
Patel, Darshak;
Pereira, Leonardo R.;
Cheeti, Sravanthi;
Musib, Luna;
Hutchinson, Katherine E.;
Devlin, Clare;
Bernardi, Ronald;
Geoerger, Birgit

Publication type:

Article

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 321, doi. 10.1007/s11523-022-00887-w

By:

Klink, Andrew J.;
Kavati, Abhishek;
Gassama, Awa T.;
Kozlek, Tom;
Gajra, Ajeet;
Antoine, Ruth

Publication type:

Article

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 271, doi. 10.1007/s11523-022-00884-z

By:

Salawu, Abdulazeez;
Hansen, Aaron R.;
Spreafico, Anna;
Al-Ezzi, Esmail;
Webster, Sheila;
Bedard, Philippe L.;
Doi, Jeffrey;
Wang, Lisa;
Siu, Lillian L.;
Abdul Razak, Albiruni R.

Publication type:

Article

Correction to: MYL-1402O: A Bevacizumab Biosimilar.

Published in:

2022

By:

Lee, Arnold

Publication type:

Correction Notice

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

Published in:

2022

By:

Shimizu, Toshio;
Kuboki, Yasutoshi;
Lin, Chia-Chi;
Yonemori, Kan;
Yanai, Tomoko;
Faller, Douglas V.;
Dobler, lwona;
Gupta, Neeraj;
Sedarati, Farhad;
Kim, Kyu-pyo

Publication type:

Correction Notice

Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 307, doi. 10.1007/s11523-022-00879-w

By:

Ishihara, Hiroki;
Nemoto, Yuki;
Nakamura, Kazutaka;
Tachibana, Hidekazu;
Fukuda, Hironori;
Yoshida, Kazuhiko;
Kobayashi, Hirohito;
Iizuka, Junpei;
Shimmura, Hiroaki;
Hashimoto, Yasunobu;
Tanabe, Kazunari;
Kondo, Tsunenori;
Takagi, Toshio

Publication type:

Article

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 295, doi. 10.1007/s11523-022-00878-x

By:

Huang, Yen-Hsiang;
Hsu, Kuo-Hsuan;
Tseng, Jeng-Sen;
Yang, Tsung-Ying;
Chen, Kun-Chieh;
Su, Kang-Yi;
Yu, Sung-Liang;
Chen, Jeremy J. W.;
Chang, Gee-Chen

Publication type:

Article

Antibody-Drug Conjugates in Uro-Oncology.

Published in:

2022

By:

Sigorski, Dawid;
Różanowski, Paweł;
Iżycka-Świeszewska, Ewa;
Wiktorska, Katarzyna

Publication type:

journal article

Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.

Published in:

Targeted Oncology, 2022, v. 17, n. 3, p. 223, doi. 10.1007/s11523-022-00876-z

By:

McLean, Thomas D.;
Duchi, Serena;
Di Bella, Claudia

Publication type:

Article